Chimerix
dose pediatric and adult tumors dose trials enrolling in parallel for adult and pediatric tumors response reported by investigator from early cohort without mutation once weekly dose is expected to intensify to three consecutive days per week national institutes of health pacific | Chimerix
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
33 of 43
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
May 2023
dose pediatric and adult tumors | Chimerix
Investor Presentation
March 2023
dose pediatric and adult tumors | Chimerix
Related slides by other companies
Genprex
Investor Presentation
October 2022
| Genprex
Aeglea BioTherapeutics
Investor Presentation
October 2023
spy phase clinical trial design | Aeglea BioTherapeutics
Genprex
Investor Presentation
November 2024
| Genprex
Immatics
Investor Presentation
November 2023
phase clinical trial to evaluate targeting | Immatics
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights